NAVAN, Inc. (NAVAN) is an early-stage private biotechnology company developing a novel, proprietary NanoStraw platform to enable the next generation of cell and gene therapies. A non-viral physical delivery technology, NanoStraws provide direct access to the cytosol of a cell and enable the delivery of Any Cargo into Any Cell in a gentle, non-perturbative manner. High cell viability, the ability to have multiple deliveries of different cargos into a cell, and no cargo size limitations are hallmarks of the platform. Cell transformation via NanoStraws will drastically reduce the complexity, cost and technical challenges involved in cell therapy manufacturing, allowing NAVAN to actively pursue the development of innovative therapies in a broad range of indications with its strategic collaborators and partners.


Dr. Craig Garner

Mr. Ryan Swoboda

Dr. Sergio Leal-Ortiz

Dr. Chris Rehse

Dr. Nick Melosh


NAVAN Closes Seed Funding Round – Investors include Amgen Ventures, HTGF and Hemi Ventures

NAVAN Technologies, Inc. (NAVAN), a privately-held biotechnology company enabling the development of next generation cell and gene therapies through its novel, non-viral NanoStraw platform, announced it had closed a seed investment round led by Amgen Ventures, High-Tech Gründerfonds (HTGF), Hemi Ventures, and other…

Info & Contact


329 Oyster Point Blvd, 3rd Floor, South San Francisco, CA 94080

In portfolio

13. Feb 2019